nursing-immunology-2019-keynote

7 / 7

Volume 3 Journal of Nursing Research and Practice Nursing & Immunology 2019
March 11-12, 2019
Page 27
Neonatology, Pediatric Nursing and Nursing
Immunology March 11-12, 2019 London, UK
World Congress on
8th World Congress on
&
Olga Kubassova, J Nursing Research and Practice, Volume 3
DOI: 10.4172/2632-251X-C1-001
Three types of artificial intelligence (AI) to impact clinical research in the next 3 years
C urrent ways of pharmaceutical Research & Development (R&D) generate poor R&D and no longer sustainable. Artificial
Intelligence (AI) is already here to Increase the speed & quality of innovation in clinical R&D. The future of successful
clinical R&D of novel therapeutic agents is dependent on the efficient use of smart modern technologies and data centric
development approach. The use of modern technologies, such as cloud platformandwearables will allow acquire large quantities
of data, often real-time and real-life; Smart ways of using data through deep learning, big data, machine learning approaches
for patient phenotyping, patient selection, trial recruitment optimization and new drug efficacy assessment will enable the
life sciences industry to increase the speed and quality of innovation, while reducing costs of development. Thus, making
AI and Machine Learning (ML) methodologies a major source of competitive advantage. Today is the right time for efficient
collaborations between the bio-pharma industry, technology companies, academic researchers, physicians and patients. A
deeper convergence between key stakeholders and advanced technologies will facilitate the discovery and development of
powerful therapies, devices and advanced diagnostics to benefit patients.
Biography
A mathematician with over 10 years expertise in actively managing innovation in life science companies, Olga Kubassova, PhD, is a healthcare innovator and biotech
investor with passion for improving people’s health. She has co-authored over 60 publications, books and book chapters, has become a scientific adviser to the UK
government and EU funding bodies. She is a founder and CEO of IAG, Image Analysis Group, the imaging clinical research organization working with top bio-pharma
companies to maximize their chances of brining novel therapeutic agents to the market. She is a four-time winner of national and international "Entrepreneur of the Year"
awards. Olga’s ambition is to bring truly disruptive technologies, artificial intelligence and best of machine learning to clinical practice and research, while expanding IAG's
footprint and partnerships.
Olga Kubassova
Image Analysis Group, UK